Wall Street brokerages expect Xencor (NASDAQ:XNCR) to post sales of $3.52 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Xencor’s earnings. The lowest sales estimate is $560,000.00 and the highest is $5.00 million. Xencor posted sales of $4.34 million in the same quarter last year, which would indicate a negative year over year growth rate of 18.9%. The firm is expected to announce its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Xencor will report full year sales of $19.92 million for the current financial year, with estimates ranging from $19.76 million to $20.00 million. For the next fiscal year, analysts forecast that the company will post sales of $19.49 million per share, with estimates ranging from $2.26 million to $28.70 million. Zacks’ sales averages are an average based on a survey of analysts that follow Xencor.
Xencor (NASDAQ:XNCR) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.02. The business had revenue of $10.94 million for the quarter, compared to analyst estimates of $15.65 million. Xencor had a negative net margin of 137.35% and a negative return on equity of 16.62%.
Several research analysts recently issued reports on XNCR shares. Zacks Investment Research reissued a “sell” rating on shares of Xencor in a research note on Saturday, January 13th. BidaskClub raised shares of Xencor from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Cantor Fitzgerald started coverage on shares of Xencor in a research note on Thursday, February 22nd. They set a “buy” rating and a $33.00 target price on the stock. Wedbush increased their target price on shares of Xencor from $38.00 to $39.00 and gave the stock an “outperform” rating in a research note on Monday, March 19th. Finally, Leerink Swann reissued an “outperform” rating and set a $36.00 target price on shares of Xencor in a research note on Wednesday, March 28th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $35.17.
Shares of NASDAQ XNCR opened at $30.62 on Wednesday. The firm has a market cap of $1,634.51, a P/E ratio of -29.28 and a beta of 1.51. Xencor has a 12-month low of $18.55 and a 12-month high of $34.63.
In other Xencor news, insider Paul A. Foster sold 10,000 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $26.03, for a total value of $260,300.00. Following the transaction, the insider now directly owns 12,419 shares of the company’s stock, valued at $323,266.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Edgardo Baracchini, Jr. sold 40,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $30.89, for a total transaction of $1,235,600.00. Following the completion of the transaction, the insider now directly owns 40,000 shares in the company, valued at $1,235,600. The disclosure for this sale can be found here. Insiders sold 105,000 shares of company stock worth $3,101,550 over the last ninety days. Insiders own 4.14% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in XNCR. Nationwide Fund Advisors lifted its stake in shares of Xencor by 4.5% in the third quarter. Nationwide Fund Advisors now owns 62,180 shares of the biopharmaceutical company’s stock valued at $1,425,000 after buying an additional 2,676 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in shares of Xencor by 158.9% in the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 4,005 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Xencor in the third quarter valued at $1,146,000. Schwab Charles Investment Management Inc. raised its holdings in shares of Xencor by 7.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 201,431 shares of the biopharmaceutical company’s stock valued at $4,416,000 after purchasing an additional 13,970 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Xencor by 14.9% in the fourth quarter. Victory Capital Management Inc. now owns 33,954 shares of the biopharmaceutical company’s stock valued at $744,000 after purchasing an additional 4,410 shares during the last quarter. 68.82% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Brokerages Anticipate Xencor (XNCR) Will Post Quarterly Sales of $3.52 Million” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/04/18/brokerages-anticipate-xencor-xncr-will-post-quarterly-sales-of-3-52-million.html.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.